Skip to main content

Current Pulmonary Hypertension Trials

Pharmaceutical Studies

A011-09 - PULSAR

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

  • Enrollment Status: Closed to Enrollment, Active in Follow-Up
  • Study Type: Interventional
  • PILeslie A. Spikes, MD

     Contact the Study Team             More Information

A011-11 - STELLAR

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (P AH) Therapy for the Treatment of PAH

     Contact the Study Team             More Information

A011-12 - SOTERIA

An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

  • Enrollment Status: Open to enrollment upon successful completion of A011-09, A011-11, A011-13 or A011-14.
  • Study Type: Interventional
  • PI: Leslie A. Spikes, MD

     Contact the Study Team             More Information 

A011-13 - HYPERION

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients

      Contact the Study Team             More Information

A011-14 - ZENITH

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk of Mortality

  • Enrollment Status: Coming Soon
  • Study Type: Interventional
  • PI: Leslie A. Spikes, MD

      Contact the Study Team             More Information

GB002-2101 - TORREY

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

      Contact the Study Team             More Information

GB002-2102 - TORREY OLE

An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

  • Enrollment Status: Open to Enrollment upon successful completion of GB002-2101
  • Study Type: Interventional
  • PI: Leslie A. Spikes, MD

     Contact the Study Team             More Information

LTI-302 - INSPIRE

A Global, Open-Label Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients

  • Enrollment Status: Closed to Enrollment, Active in Follow-Up
  • Study Type: Interventional
  • PI: Leslie A. Spikes, MD

     Contact the Study Team             More Information

MK-5475

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension

     Contact the Study Team              More Information

PB1046-PT-CL-0004

A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous Injections of a Sustained- Release VIP Analogue, PB1046, in Adult Subjects with Symptomatic Pulmonary Arterial Hypertension

     Contact the Study Team              More Information

PB1046-PT-CL-0006

A Long-Term, Open label Extension Study of PB1046 Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004

  • Enrollment Status: Open to Enrollment upon successful completion of PB1046-PT-CL-0004
  • Study Type: Interventional
  • PI: Leslie A. Spikes, MD

     Contact the Study Team             More Information

RiOciguAt UseRs Registry - The ROAR Registry

      Contact the Study Team            More Information

RT234-PAH-CL202

A Phase 2, Open-label, Dose Escalation Study to Evaluate the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects with Pulmonary Arterial Hypertension (PAH)

     Contact the Study Team             More Information

RVT-1201-2002 - ELEVATE 2

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension

     Contact the Study Team             More Information

TIP-PH-101 - BREEZE

An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects with Pulmonary Arterial Hypertension Currently Using Tyvaso

  • Enrollment Status: Closed to Enrollment, Active in Follow-Up
  • Study Type: Interventional
  • PI: Leslie A. Spikes, MD

     Contact the Study Team              More Information

PHAR - Pulmonary Hypertension Association Registry

     Contact the Study Team             More Information


Investigator Initiated (Pulmonary Hypertension)

PHBR - Pulmonary Hypertension Biorepository & Registry

     Contact the Study Team              More Information

    

Last modified: Jul 16, 2021
ID=x36919